Crossref
Spesolimab in the FDA Adverse Event Reporting System: A Disproportionality Analysis
Journal of Pharmacy Technology · 21.11.2026
DOI: 10.1177/87551225261508397 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy Technology, online erschienen am 21.11.2026. Verfasst von Ahmet Uğur Atılan und 1 weiteren Autor:innen. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Atılan, A. U., & çetin, N. (2026). Spesolimab in the FDA Adverse Event Reporting System: A Disproportionality Analysis. Journal of Pharmacy Technology. https://doi.org/10.1177/87551225261508397
Vancouver
Atılan AU, çetin N. Spesolimab in the FDA Adverse Event Reporting System: A Disproportionality Analysis. Journal of Pharmacy Technology. 2026. doi:10.1177/87551225261508397
BibTeX
@article{Atlan2026,
author = {Atılan, Ahmet Uğur and çetin, Niyazi},
title = {Spesolimab in the FDA Adverse Event Reporting System: A Disproportionality Analysis},
journal = {Journal of Pharmacy Technology},
year = {2026},
doi = {10.1177/87551225261508397}
}
EUVIMED